Lancashire and South Cumbria
Formulary
Formulary
7 Obstetrics, Gynaecology, and urinary-tract disorders
07-04-05 Phosphodiesterase type 5 inhibitors
| Sildenafil |
|
Formulary
|
Tablets 25mg, 50mg, 100mg Erectile dysfunction. First line pharmacological therapy for erectile dysfunction. |
 LSCMMG: Primary Care Management of Erectile Dysfunction |
|
| Tadalafil once daily |
|
Formulary
|
5mg Tablets For the treatment of erectile dysfunction. 2.5mg tablets are restricted for when the 5mg daily dose is not tolerated. Tadalafil daily 5mg tablets are suitable for initiation in primary care. |
|
LSCMMG: Primary Care Management of Erectile Dysfunction |
|
|
| Tadalafil all preparations |
|
Formulary
|
Benign prostatic hyperplasia |
 NICE TA273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) |
|
| Avanafil Spedra® |
|
Formulary
|
Tablets 50mg, 100mg, 200mg Erectile Dysfunction. Treatment of erectile dysfunction in adult men who are unable to tolerate sildenafil and tadalafil. |
|
LSCMMG: Primary Care Management of Erectile Dysfunction |
|
| Vardenafil |
|
Formulary
|
Erectile Dysfunction. |
|
LSCMMG: Primary Care Management of Erectile Dysfunction |
|
|
Links
- FSRH Clinical Guideline: Contraceptive Choices for Young People
- FSRH: Standards & Guidance
- FSRH: UK Medical Eligibility Criteria for Contraceptive Use (UKMEC)
- Generic sildenafil (QIPP) information
- Generic sildenafil (QIPP) information supporting information
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Erectile Dysfunction
- LSCMMG: Primary Care Management of Overactive Bladder in Female Adults
- MHRA Drug Safety Update Nov 2018: Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction
- MHRA: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?
- NICE CG30: Long-acting reversible contraception
- NICE CG97: Lower urinary tract symptoms in men: management
- NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management
- NICE NG133: Hypertension in pregnancy: diagnosis and management
- NICE NG194: Postnatal care
- NICE NG210: Pelvic floor dysfunction: prevention and non-surgical management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE NG88: Heavy menstrual bleeding: assessment and management
- NICE TA273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)
- NICE: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)